Lynparza development takes step forward in early breast cancer

PARP blocker Lynparza (olaparib), the first medicine targeting BRCA mutations to show clinical benefit in the adjuvant setting, is now under US Food and Drug Administration priority review, with a decision due by the first quarter of 2022.

Together with Merck & Co (NYSE: MRK), AstraZeneca (LSE: AZN) is developing the therapy for the adjuvant treatment of BRCA-mutated HER2-negative high-risk early breast cancer.

The regulatory submission is backed by data from the Phase III OlympiA trial, which enrolled people who were already treated with chemotherapy, either before or after surgery.